Tactile Systems (TCMD) Stock Forecast & Price Target

Tactile Systems Tech is supported by a large, under-penetrated lymphedema market, strong demand for its at-home Flexitouch, Nimbl, and Entre therapies, and a favorable Medicare NCD that has helped lift adoption, especially in the Medicare channel. The company also benefits from improving execution after a FY25 transformation, with 1Q26 revenue of $75.3M rising 23% in lymphedema and 22% in airway clearance, while gross margin of 76.5% beat expectations by about 420 bps and FY26 revenue guidance increased to $360M-$368M. Even with near-term Airway Clearance inventory digestion and prior authorization noise, its #1 share position in airway clearance, expanding sales productivity, and steady FY26 adjusted EBITDA guidance of $49M-$51M support a constructive fundamental outlook.

Tactile Systems Tech is facing a cautious fundamental outlook because commercial-channel adoption may remain slower than expected, while Medicare documentation burdens, coverage confusion, and differing physician views on pneumatic compression could restrain demand. The company ended 2Q26 with 332 sales reps, down 3 from 1Q26, and management cut FY26 revenue guidance to $360 million-$366 million from $360 million-$368 million as Airway Clearance softened. Although adjusted EBITDA guidance of $49 million-$51 million and gross margins of 76%-77% suggest some operational stability, the need to spend more on sales effectiveness and SBC highlights limited leverage and execution risk.